JP2006510733A - カルジオリピン分子および合成方法 - Google Patents

カルジオリピン分子および合成方法 Download PDF

Info

Publication number
JP2006510733A
JP2006510733A JP2005501873A JP2005501873A JP2006510733A JP 2006510733 A JP2006510733 A JP 2006510733A JP 2005501873 A JP2005501873 A JP 2005501873A JP 2005501873 A JP2005501873 A JP 2005501873A JP 2006510733 A JP2006510733 A JP 2006510733A
Authority
JP
Japan
Prior art keywords
cardiolipin
composition
liposome
acid
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005501873A
Other languages
English (en)
Japanese (ja)
Inventor
アフマド、モジス、ユー．
ウカラン、ムラリ、ケイ．
アフマド、イムラン
Original Assignee
ネオファーム、インコーポレイティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/013917 external-priority patent/WO2004062569A2/en
Priority claimed from PCT/US2003/016412 external-priority patent/WO2003099830A2/en
Application filed by ネオファーム、インコーポレイティッド filed Critical ネオファーム、インコーポレイティッド
Publication of JP2006510733A publication Critical patent/JP2006510733A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
JP2005501873A 2002-10-16 2003-09-05 カルジオリピン分子および合成方法 Pending JP2006510733A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US41927702P 2002-10-16 2002-10-16
US60/419,277 2002-10-16
US42928502P 2002-11-26 2002-11-26
US60/429,285 2002-11-26
US43865903P 2003-01-07 2003-01-07
US60/438,659 2003-01-07
US46733103P 2003-05-02 2003-05-02
US60/467,331 2003-05-02
PCT/US2003/013917 WO2004062569A2 (en) 2003-01-07 2003-05-04 Cardiolipin compositions their methods of preparation and use
USPCT/US03/13917 2003-05-04
USPCT/US03/16412 2003-05-23
PCT/US2003/016412 WO2003099830A2 (en) 2002-05-24 2003-05-23 Cardiolipin compositions, methods of preparation and use
PCT/US2003/027806 WO2004039817A1 (en) 2002-10-16 2003-09-05 Cardiolipin molecules and method of synthesis

Publications (1)

Publication Number Publication Date
JP2006510733A true JP2006510733A (ja) 2006-03-30

Family

ID=32234368

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2005501873A Pending JP2006510733A (ja) 2002-10-16 2003-09-05 カルジオリピン分子および合成方法
JP2005501473A Pending JP2006503112A (ja) 2002-10-16 2003-10-16 陽イオン性カルジオリピン類似体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2005501473A Pending JP2006503112A (ja) 2002-10-16 2003-10-16 陽イオン性カルジオリピン類似体およびその使用

Country Status (7)

Country Link
EP (2) EP1556392A1 (ru)
JP (2) JP2006510733A (ru)
AU (2) AU2003268478A1 (ru)
CA (2) CA2502285A1 (ru)
EA (2) EA200500659A1 (ru)
HK (1) HK1080087A1 (ru)
WO (2) WO2004039817A1 (ru)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514123A (ja) * 2012-04-11 2015-05-18 リポクセン テクノロジーズ リミテッド ミエリン塩基性タンパク質のオリゴペプチドフラグメントを含有するリポソーム、医薬組成物および多発性硬化症の治療方法
JP2017048188A (ja) * 2008-09-27 2017-03-09 ジャイナ ファーマシューティカルズ，インコーポレーテッド 経口適用および局所適用のための脂質系薬学的調製物、ならびにそれらの組成物、方法、および使用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
WO2006004935A2 (en) * 2004-06-29 2006-01-12 Neopharm, Inc. Pegylated cardiolipin analogs, methods of synthesis, and uses thereof
MX2007005591A (es) * 2004-11-08 2008-02-12 Neopharm Inc Sintesis de analogos de cardiolipina y usos de los mismos.
AU2006236453B2 (en) 2005-01-25 2012-02-23 Board Of Regents, The University Of Texas System Delivery of siRNA by neutral lipid compositions
WO2007014150A2 (en) * 2005-07-22 2007-02-01 Neopharm, Inc. Method of administering liposomes containing oligonucleotides
CA2631677C (en) 2005-12-01 2014-08-12 Pronai Therapeutics, Inc. Amphoteric liposome formulation
WO2007065017A2 (en) * 2005-12-01 2007-06-07 Pronai Therapeutics, Inc. Oligonucleotide cationic liposomal delivery system
EP1986607A4 (en) * 2006-02-24 2010-02-10 Neopharm Inc METHOD AND PROCESS FOR THE PRODUCTION OF CARDIOLIPIN

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2113606A (en) * 1934-05-24 1938-04-12 Alba Pharmaceutical Company In Quaternary ammonium compounds
US6461637B1 (en) * 2000-09-01 2002-10-08 Neopharm, Inc. Method of administering liposomal encapsulated taxane
ATE383331T1 (de) * 1998-11-12 2008-01-15 Invitrogen Corp Transportreagentien
WO2000073263A1 (en) * 1999-05-28 2000-12-07 Vical Incorporated Cytofectin dimers and methods of use thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017048188A (ja) * 2008-09-27 2017-03-09 ジャイナ ファーマシューティカルズ，インコーポレーテッド 経口適用および局所適用のための脂質系薬学的調製物、ならびにそれらの組成物、方法、および使用
JP2015514123A (ja) * 2012-04-11 2015-05-18 リポクセン テクノロジーズ リミテッド ミエリン塩基性タンパク質のオリゴペプチドフラグメントを含有するリポソーム、医薬組成物および多発性硬化症の治療方法

Also Published As

Publication number Publication date
EP1556392A1 (en) 2005-07-27
AU2003268478A1 (en) 2004-05-25
WO2004039817A9 (en) 2004-07-22
EA200500661A1 (ru) 2005-10-27
WO2004039817A1 (en) 2004-05-13
WO2004035523B1 (en) 2004-08-26
CA2502285A1 (en) 2004-05-13
AU2003277445A1 (en) 2004-05-04
CA2501990A1 (en) 2004-04-29
JP2006503112A (ja) 2006-01-26
WO2004035523A1 (en) 2004-04-29
EP1558562A1 (en) 2005-08-03
EA200500659A1 (ru) 2005-10-27
HK1080087A1 (zh) 2006-04-21

Similar Documents

Publication Publication Date Title
US20050266068A1 (en) Cardiolipin molecules and methods of synthesis
US20050181037A1 (en) Cardiolipin compositions their methods of preparation and use
US20050277611A1 (en) Cationic cardiolipin analoges and its use thereof
US20170210775A1 (en) Guggulphospholipid methods and compositions
US20170152223A1 (en) Lipid particles with cationic lipids for rna delivery
US8129552B2 (en) Phospholipids with unsaturated alkyl and acyl chains
CA2968060A1 (en) Ionizable cationic lipid for rna delivery
US20080286351A1 (en) Pegylated Cardiolipin Analogs, Methods of Synthesis, and Uses Thereof
CN1416431A (zh) 核苷化合物及其应用
JP2006510733A (ja) カルジオリピン分子および合成方法
US6696081B2 (en) Carbohydrate based lipid compositions and supramolecular structures comprising same
WO2012119780A2 (en) Novel lipids and novel phospholipids structures
US20080300418A1 (en) Synthesis of Cardiolipin Analogues and Uses Thereof
JP2023533864A (ja) 式－ｎｈ－ｃｘ－ａまたは－ｎｈ－ｃｘ－ｎｈ－ａの少なくとも１つの末端ラジカルを含む脂質化合物、それらを含有する組成物およびそれらの使用
JP2001515082A (ja) リン脂質類似化合物
CN1714095A (zh) 心磷脂分子及合成方法
WO2004062569A2 (en) Cardiolipin compositions their methods of preparation and use
CN1714094A (zh) 心磷脂组合物及它们制备的方法和应用
JP2003522203A (ja) 天然に存在しない核酸組成物、核酸を細胞中にトランスフェクションするのに有用な処方物の調製のためのそれらの使用、および応用
WO2024019770A1 (en) Methods of making ionizable lipids and lipid nanoparticles for mrna delivery

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060811

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20090224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090630

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100223